Volume 95 Issue 11 | p. 15 | Concentrates
Issue Date: March 13, 2017

Boehringer, Vanderbilt pact targets KRAS

Department: Business
Keywords: oncology, pharmaceuticals, partnership, KRAS
[+]Enlarge
A researcher in the Fesik lab at Vanderbilt.
Credit: Vanderbilt
A photo of a researcher in the Fesik lab at Vanderbilt.
 
A researcher in the Fesik lab at Vanderbilt.
Credit: Vanderbilt

Advancing a two-year-old cancer drug discovery partnership, Boehringer Ingelheim and Vanderbilt University will research and develop small molecules targeting a protein called SOS that acts as a molecular switch activating KRAS, a gene essential to normal tissue signaling. Mutations of the gene are responsible for the onset of various forms of cancer. The venture is based on research done in the laboratory of Vanderbilt chemist Stephen W. Fesik. The partners previously identified compounds that bind to KRAS with high affinity.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment